{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28drug%29&page=3",
    "query": {
      "intervention": "Rifaximin (drug)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 74,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28drug%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28drug%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T14:12:56.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05159427",
      "title": "Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Gastrointestinal Physiology Data"
      ],
      "interventions": [
        {
          "name": "Glucotrol XL 5Mg Extended-Release Tablet",
          "type": "DRUG"
        },
        {
          "name": "Glipizide ER 5 MG 24 HR Extended Release Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin 200Mg Tab",
          "type": "DRUG"
        },
        {
          "name": "13C6-Glipizide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-03-15",
      "completion_date": "2026-03-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05159427"
    },
    {
      "nct_id": "NCT00680836",
      "title": "Gulf War Digestive Health Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Irritable Bowel Syndrome",
        "Small Intestinal Bacterial Overgrowth"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "35 Years to 72 Years"
      },
      "enrollment_count": 54,
      "start_date": "2007-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2014-08-29",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680836"
    },
    {
      "nct_id": "NCT00956397",
      "title": "Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Functional Dyspepsia",
        "Small Intestinal Bacterial Overgrowth",
        "Chronic Abdominal Discomfort"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Lactulose Breath Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Henry C. Lin, MD",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2007-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-10-24",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00956397"
    },
    {
      "nct_id": "NCT05150587",
      "title": "Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Papulopustular Rosacea"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alfasigma S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2021-10-05",
      "completion_date": "2022-10-20",
      "has_results": true,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 38,
      "location_summary": "Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more",
      "locations": [
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05150587"
    },
    {
      "nct_id": "NCT07209371",
      "title": "Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Monoclonal Gammopathy of Undetermined Significance",
        "Non-IgM Monoclonal Gammopathy of Undetermined Significance"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-01-22",
      "completion_date": "2028-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209371"
    },
    {
      "nct_id": "NCT00945334",
      "title": "Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Constipation-predominant Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Neomycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Pimentel, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 37,
      "start_date": "2009-08",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2015-08-10",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Augusta, Georgia",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00945334"
    },
    {
      "nct_id": "NCT02376972",
      "title": "Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BACTERIAL VAGINOSIS"
      ],
      "interventions": [
        {
          "name": "RIFAXIMIN VAGINAL TABLET 25 MG",
          "type": "DRUG"
        },
        {
          "name": "RIFAXIMIN VAGINAL TABLET 100 MG",
          "type": "DRUG"
        },
        {
          "name": "PLACEBO VAGINAL TABLET",
          "type": "DRUG"
        },
        {
          "name": "METROGEL VAGINAL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alfasigma S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 392,
      "start_date": "2015-04",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-10-10",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02376972"
    },
    {
      "nct_id": "NCT04254549",
      "title": "Rifaximin in Patients With Diabetic Gastroparesis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease",
        "Diabetic Gastroparesis"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-06-14",
      "completion_date": "2025-04-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04254549"
    },
    {
      "nct_id": "NCT03712280",
      "title": "MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Cirrhosis",
        "Hepatic Encephalopathy (HE)"
      ],
      "interventions": [
        {
          "name": "MNK6106",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2018-12-01",
      "completion_date": "2020-07-14",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 4,
      "location_summary": "Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712280"
    },
    {
      "nct_id": "NCT06312683",
      "title": "Rifaximin for the Secondary Prevention of Recurrent Pouchitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pouchitis"
      ],
      "interventions": [
        {
          "name": "Rifaximin 550 MG Oral Tablet [XIFAXAN]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 16,
      "start_date": "2024-07-01",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-10T14:12:56.455Z",
      "location_count": 2,
      "location_summary": "New York, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312683"
    }
  ]
}